Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 18/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | MTOR | P42345 | 2/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.43 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.43 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14301330 | 0.93 | PIK3CA (0.58) | PIK3CAKDM4EALDH1A1GLAGAA | |
| SCHEMBL1897045 | 0.83 | PIK3CA (0.70) | PIK3CAKDM4EALDH1A1GLAGAA | |
| SCHEMBL189075 | 0.83 | ALDH1A1 (0.73) | PIK3CAKDM4EALDH1A1GLAGAA | |
| SCHEMBL14301329 | 0.81 | PIK3CA (0.57) | PIK3CAKDM4EALDH1A1GLAGAA | |
| SCHEMBL188994 | 0.77 | ALDH1A1 (0.70) | PIK3CAKDM4EALDH1A1GLAGAA | |
| SCHEMBL1987016 | 0.76 | PIK3CA (1.00) | PIK3CAKDM4EALDH1A1GLAGAA | |
| SCHEMBL1896964 | 0.75 | PIK3CA (0.62) | PIK3CAKDM4EALDH1A1GLAGAA | |
| SCHEMBL5116317 | 0.71 | ALDH1A1 (0.46) | PIK3CAKDM4EALDH1A1GLAGAA | |
| SCHEMBL3330263 | 0.70 | PIK3CA (1.00) | PIK3CAKDM4EALDH1A1GLAGAA | |
| SCHEMBL1897414 | 0.70 | PIK3CA (0.58) | PIK3CAMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008021389-A2 | USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER | EXELIXIS, INC. (US) | 2008-02-21 | — | — | WO | disclosed |